Bacteremia: A Meta???analysis, Clinical Infectious Diseases, vol.36, issue.1, pp.53-59, 2003. ,
DOI : 10.1086/345476
The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use, Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull, vol.17, 2012. ,
Relationship between consumption of MRSA-active antibiotics and burden of MRSA in acute care hospitals in Catalonia, Spain, Journal of Antimicrobial Chemotherapy, 2014. ,
DOI : 10.1093/jac/dku487
Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004???2009, International Journal of Antimicrobial Agents, vol.37, issue.3, pp.219-224, 2004. ,
DOI : 10.1016/j.ijantimicag.2010.10.029
Linezolid resistance in a clinical isolate of Staphylococcus aureus, The Lancet, vol.358, issue.9277, pp.207-208, 2001. ,
DOI : 10.1016/S0140-6736(01)05410-1
Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis, International Journal of Antimicrobial Agents, vol.27, issue.4, pp.300-302, 2006. ,
DOI : 10.1016/j.ijantimicag.2005.11.008
Improving linezolid use decreases the incidence of resistance among Gram-positive microorganisms, International Journal of Antimicrobial Agents, vol.41, issue.2, pp.174-178, 2013. ,
DOI : 10.1016/j.ijantimicag.2012.10.017
Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data, Medical Care, vol.43, issue.11, pp.1130-1139, 2005. ,
DOI : 10.1097/01.mlr.0000182534.19832.83
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children, Clinical Infectious Diseases, vol.52, issue.3, pp.18-55, 2011. ,
DOI : 10.1093/cid/ciq146
Management of methicillin-resistant Staphylococcus aureus infections, Clinical Microbiology and Infection, vol.15, issue.2, pp.125-136, 2009. ,
DOI : 10.1111/j.1469-0691.2009.02701.x
Management of methicillin-resistant Staphylococcus aureus infections, Clinical Microbiology and Infection, vol.15, issue.2, pp.125-136, 2009. ,
DOI : 10.1111/j.1469-0691.2009.02701.x
European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid, Clinical Microbiology and Infection, vol.20, pp.19-36, 2014. ,
DOI : 10.1111/1469-0691.12450
The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections, PLoS ONE, vol.14, issue.3, p.58240, 2013. ,
DOI : 10.1371/journal.pone.0058240.s002
Linezolid vs Glycopeptide Antibiotics for the Treatment of Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia, Chest, vol.139, issue.5, pp.1148-1155, 2011. ,
DOI : 10.1378/chest.10-1556
Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections, Clinical Pharmacokinetics, vol.50, issue.6, pp.925-942, 2004. ,
DOI : 10.2165/00003088-200443130-00005
Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?, Clinical Infectious Diseases, vol.59, issue.5, pp.666-675, 2014. ,
DOI : 10.1093/cid/ciu398
Relationship between Initial Vancomycin Concentration???Time Profile and Nephrotoxicity among Hospitalized Patients, Clinical Infectious Diseases, vol.49, issue.4, pp.507-514, 2009. ,
DOI : 10.1086/600884
Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter, Antimicrobial Agents and Chemotherapy, vol.57, issue.2, pp.734-744, 2013. ,
DOI : 10.1128/AAC.01568-12
Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year Period, Journal of Clinical Microbiology, vol.44, issue.11, pp.3883-3886, 2006. ,
DOI : 10.1128/JCM.01388-06
Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006, Clinical Infectious Diseases, vol.46, issue.5, pp.668-674, 2002. ,
DOI : 10.1086/527392
Staphylococcus aureus meningitis with intermediate sensitivity to glycopeptides. Therapeutic indications].PresseMédicale Paris Fr, pp.217-220, 1983. ,
Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates, Antimicrobial Agents and Chemotherapy, vol.55, issue.1, pp.405-410, 2011. ,
DOI : 10.1128/AAC.01133-10
Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia, Journal of Clinical Microbiology, vol.42, issue.6, pp.2398-2402, 2004. ,
DOI : 10.1128/JCM.42.6.2398-2402.2004
Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin, Antimicrobial Agents and Chemotherapy, vol.52, issue.9, pp.3315-3320, 2008. ,
DOI : 10.1128/AAC.00113-08
Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin, European Journal of Medical Research, vol.15, issue.12, pp.533-543, 2010. ,
DOI : 10.1186/2047-783X-15-12-533
Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial, Pharmacotherapy, vol.14, issue.3, pp.263-274, 2001. ,
DOI : 10.1016/0002-9343(91)90181-V
Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections, Journal of Antimicrobial Chemotherapy, vol.51, issue.90002, pp.17-25, 2003. ,
DOI : 10.1093/jac/dkg248
MRSA: the first half century, Journal of Antimicrobial Chemotherapy, vol.67, issue.1, pp.4-11, 2012. ,
DOI : 10.1093/jac/dkr437
Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12), Journal of Antimicrobial Chemotherapy, vol.69, issue.6, pp.1582-1588, 2014. ,
DOI : 10.1093/jac/dkt541
The emerging problem of linezolid-resistant Staphylococcus, Journal of Antimicrobial Chemotherapy, vol.68, issue.1, pp.4-11, 2013. ,
DOI : 10.1093/jac/dks354
Factors affecting the uptake of new medicines in secondary care a literature review, Journal of Clinical Pharmacy and Therapeutics, vol.332, issue.4, pp.339-348, 2008. ,
DOI : 10.1111/j.1365-2710.2008.00925.x
Linezolid vs Vancomycin*, Chest, vol.124, issue.5, pp.1789-1797, 2003. ,
DOI : 10.1016/S0012-3692(15)33412-7
Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study, Clinical Infectious Diseases, vol.54, issue.5, pp.621-629, 2012. ,
DOI : 10.1093/cid/cir895
Intrapulmonary Pharmacokinetics of Linezolid, Antimicrobial Agents and Chemotherapy, vol.46, issue.5, pp.1475-1480, 2002. ,
DOI : 10.1128/AAC.46.5.1475-1480.2002
The ZEPHyR study: A randomized comparison of linezolid and vancomycin for MRSA pneumonia, M??decine et Maladies Infectieuses, vol.43, issue.11-12, pp.451-455, 2013. ,
DOI : 10.1016/j.medmal.2013.09.011
Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis, Journal of Antimicrobial Chemotherapy, vol.70, issue.2, pp.382-395, 2015. ,
DOI : 10.1093/jac/dku379
Impact of Empirical-Therapy Selection on Outcomes of Intravenous Drug Users with Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus, Antimicrobial Agents and Chemotherapy, vol.51, issue.10, pp.3731-3733, 2007. ,
DOI : 10.1128/AAC.00101-07
Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies, Journal of Antimicrobial Chemotherapy, vol.56, issue.5, pp.923-929, 2005. ,
DOI : 10.1093/jac/dki355
Bacteremia, JAMA, vol.312, issue.13, pp.1330-1341, 2014. ,
DOI : 10.1001/jama.2014.9743
Inadequate Antimicrobial Treatment of Infections, Chest, vol.115, issue.2, pp.462-474, 1999. ,
DOI : 10.1378/chest.115.2.462
Surviving Sepsis Campaign, Critical Care Medicine, vol.41, issue.2, pp.165-228, 2013. ,
DOI : 10.1097/CCM.0b013e31827e83af
Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey, Diagnostic Microbiology and Infectious Disease, vol.62, issue.4, pp.407-410, 2008. ,
DOI : 10.1016/j.diagmicrobio.2008.08.009
Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics, Can. Fam. Physician Médecin Fam. Can, vol.44, pp.1769-1773, 1998. ,
Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion, International Journal of Antimicrobial Agents, vol.31, issue.2, pp.122-129, 2008. ,
DOI : 10.1016/j.ijantimicag.2007.09.009
Prospective assessment of fluoroquinolone use in a teaching hospital, European Journal of Clinical Microbiology & Infectious Diseases, vol.6, issue.12, pp.757-763, 2006. ,
DOI : 10.1007/s10096-006-0221-0
Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus, Critical Care, vol.18, issue.4, p.157, 2014. ,
DOI : 10.1186/cc13996
Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus, Clinical Therapeutics, vol.28, issue.8, pp.1184-1198, 2006. ,
DOI : 10.1016/j.clinthera.2006.08.016
Multiresistant bacteria and current therapy - the economical side of the story, European Journal of Medical Research, vol.15, issue.12, pp.571-576, 2010. ,
DOI : 10.1016/j.diagmicrobio.2008.09.001
Register-based indicators for potentially inappropriate medication in high-cost patients with excessive polypharmacy, Pharmacoepidemiology and Drug Safety, vol.31, issue.Pt 1, 2015. ,
DOI : 10.1002/pds.3764
Vancomycin-Resistant Enterococcal Urinary Tract Infections, Pharmacotherapy, vol.15, issue.47, pp.1136-1149, 2010. ,
DOI : 10.1056/NEJM199310283291808
Successful Treatment of Chronic Bone and Joint Infections with Oral Linezolid, Clinical Orthopaedics and Related Research, vol.427, pp.67-71, 2004. ,
DOI : 10.1097/01.blo.0000144860.11193.5e
Linezolid for the treatment of adults with bone and joint infections, International Journal of Antimicrobial Agents, vol.29, issue.3, pp.233-239, 2007. ,
DOI : 10.1016/j.ijantimicag.2006.08.030
Infections among Patients in the Emergency Department, New England Journal of Medicine, vol.355, issue.7, pp.666-674, 2006. ,
DOI : 10.1056/NEJMoa055356
Linezolid audit: similarities and contrasts with published experience, Journal of Antimicrobial Chemotherapy, vol.57, issue.5, pp.1008-1009, 2006. ,
DOI : 10.1093/jac/dkl090
Clinical audit of linezolid use in a large teaching hospital, Journal of Antimicrobial Chemotherapy, vol.56, issue.2, pp.423-426, 2005. ,
DOI : 10.1093/jac/dki185
An assessment of linezolid utilization in selected canadian provinces. Can, J. Infect. Dis. Med. Microbiol. J. Can. Mal. Infect. Microbiol. Médicale AMMI Can, vol.17, pp.177-182, 2006. ,